Cargando…
Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts
PURPOSE: Clinical trials and epidemiological evidence have shown that combined estrogen/progestin hormone replacement therapy, but not estrogen therapy alone, increases breast cancer risk in post-menopausal women. Previously we have shown that natural and synthetic progestins, including the widely u...
Autores principales: | Cook, Matthew T., Liang, Yayun, Besch-Williford, Cynthia, Goyette, Sandy, Mafuvadze, Benford, Hyder, Salman M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546074/ https://www.ncbi.nlm.nih.gov/pubmed/26312209 http://dx.doi.org/10.1186/s40064-015-1242-x |
Ejemplares similares
-
A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
por: Liang, Yayun, et al.
Publicado: (2018) -
Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro
por: Goyette, Sandy, et al.
Publicado: (2017) -
Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
por: Cook, Matthew T, et al.
Publicado: (2016) -
Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
por: Liang, Yayun, et al.
Publicado: (2017) -
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development
por: CARROLL, CANDACE E., et al.
Publicado: (2012)